2-(N-methylamino)-4-((o-methoxy)phenyl)thiazole | 849483-71-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-(N-methylamino)-4-((o-methoxy)phenyl)thiazole
• 英文别名: 4-(2-methoxyphenyl)-N-methylthiazol-2-amine；4-(2-methoxyphenyl)-N-methyl-1,3-thiazol-2-amine
• CAS: 849483-71-2
• 化学式: C₁₁H₁₂N₂OS
• mdl: MFCD07269205
• 分子量: 220.295
• InChiKey: ZHHOXJFXQNQOSA-UHFFFAOYSA-N

物化性质

• 沸点：
  332.7±34.0 °C(Predicted)
• 密度：
  1.217±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.181
• 拓扑面积：
  62.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  邻甲氧基-2-溴苯乙酮 、 N-甲硫脲 以 乙醇 为溶剂， 反应 0.17h， 生成 2-(N-methylamino)-4-((o-methoxy)phenyl)thiazole
  参考文献：
  名称：

  [EN] CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER
  [FR] CYANOPYRROLIDINES EN TANT QU'INHIBITEURS DES DUB POUR LE TRAITEMENT DU CANCER

  摘要：

  本发明涉及新型化合物和制备去泛素酶（DUBs）抑制剂的方法。具体而言，本发明涉及抑制泛素C-末端水解酶L1（UCHL1）和泛素C-末端水解酶30或泛素特异性肽酶30（USP30）。本发明还涉及在治疗癌症和涉及线粒体功能障碍的疾病中使用DUB抑制剂。本发明的化合物包括具有以下式（I）或其药用可接受盐的化合物，其中R1、R2、R3、R4、R5、R6、R7、R8和R9如本文所定义。

  公开号：

  WO2017009650A1

文献信息

• Effect of Substituents on the Regioselectivity of the Reaction of α-Tosyloxyketones with Thioureas in Acidic Medium: Access to 2-Aminothiazoles and 2-Imino-2,3-dihydrothiazoles
  作者：Ranjana Aggarwal、Rajiv Kumar、Dionisia Sanz、Rosa M. Claramunt

  DOI：10.1002/jhet.1676

  日期：2014.5

  Regioselective condensation of α‐tosyloxyacetophenones 1 and N‐substituted thioureas 2 in acidic medium to give regioisomers 2‐aminothiazoles I and 2‐imino‐2,3‐dihydrothiazoles II is largely influenced by the substituents present on 1 and 2. A mechanism, supported by DFT calculations has been proposed to explain the observed regioselectively.

  α-甲苯磺酰氧基苯乙酮1和N-取代的硫脲2在酸性介质中的区域选择性缩合反应产生区域异构体2-氨基噻唑I和2-亚氨基-2,3-二氢噻唑II在很大程度上受到1和2上存在的取代基的影响。已经提出了一种由DFT计算支持的机制来选择性地解释所观察到的区域。
• NOVEL COMPOUND HAVING ANTICANCER ACTIVITY, AND METHOD FOR PRODUCING SAME
  申请人：MEDICINAL BIOCONVERGENCE RESEARCH CENTER

  公开号：US20220204497A1

  公开（公告）日：2022-06-30

  The present invention pertains to a novel compound having anticancer activity, and a method for producing same, and more specifically, to a novel compound that exhibits excellent anticancer activity by inhibiting the expression of AIMP2-DX2, and a method for producing same. The compound represented by chemical formula 1 according to the present invention is highly effective in inhibiting the expression of AIMP2-DX2, and thus can be very advantageously used for the development of agents for treating various diseases, in particular cancer, caused by AIMP2-DX2.
• [EN] CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER<br/>[FR] CYANOPYRROLIDINES EN TANT QU'INHIBITEURS DES DUB POUR LE TRAITEMENT DU CANCER
  申请人：MISSION THERAPEUTICS LTD

  公开号：WO2017009650A1

  公开（公告）日：2017-01-19

  The present invention relates to novel compounds and method for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C- terminal hydrolase L1 (UCHL1) and ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of cancer and conditions involving mitochondrial dysfunction. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1,R2,R3,R4,R5,R6,R7,R8 and R9 are as defined herein.

  本发明涉及新型化合物和制备去泛素酶（DUBs）抑制剂的方法。具体而言，本发明涉及抑制泛素C-末端水解酶L1（UCHL1）和泛素C-末端水解酶30或泛素特异性肽酶30（USP30）。本发明还涉及在治疗癌症和涉及线粒体功能障碍的疾病中使用DUB抑制剂。本发明的化合物包括具有以下式（I）或其药用可接受盐的化合物，其中R1、R2、R3、R4、R5、R6、R7、R8和R9如本文所定义。